EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP)

Mehmet Kanbay iD, Sidar Copur, Pantelis Sarafidis, Charles J Ferro iD, Alberto Ortiz iD

Nephrology Dialysis Transplantation · 2026

DOI: 10.1093/ndt/gfag055 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nephrology Dialysis Transplantation, 2026. Verfasst von Mehmet Kanbay und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey. Hauptthemen laut MEDLINE: Hypertension, Practice Guidelines as Topic, Antihypertensive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Comunidad de Madrid en Biomedicina, Instituto de Salud Carlos III, European Union.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

American Scientific Societies (AHA/ACC and others) updated in 2025 the guideline on High Blood Pressure following 2024 ESC and 2023 ESH updates from Europe. Guidelines mostly agree on who should receive pharmacotherapy and on a common target of systolic blood pressure (SBP; <130 mmHg) and diastolic blood pressure (DBP) <80 mmHg for most, as well as on individualizing BP targets according to patient characteristics. However, they differ in nomenclature, pharmacotherapy for people at lower cardiovascular risk and aiming at SBP <120 mmHg. Overall, 2025 AHA/ACC supports pharmacotherapy earlier and achieving lower BP targets than other recent guidelines: it recommends [high cardiovascular disease (CVD) risk] or finds reasonable (not high CVD risk, if not corrected by lifestyle) initiating pharmacotherapy for hypertension, defined as SBP ≥130 mmHg or DBP ≥80 mmHg. The recommended (high CVD risk) or reasonable (not high CVD risk) target is SBP at least <130 mmHg, with encouragement to achieve SBP <120 mmHg, and DBP <80 mmHg. However, 2024 ESC and 2023 ESH use alternative terms (high normal or elevated blood pressure) for blood pressure values (i.e. ≥130–139 or ≥80–89 mmHg) that require pharmacotherapy only in high-risk groups. Additionally, 2023 ESH recommends avoiding actively aiming for SBP <120 mmHg or DBP <70 mmHg. 2024 KDIGO avoids the term hypertension and suggests a target SBP <120 mmHg for people with chronic kidney disease. It would be desirable that guidelines converge on such key issues as nomenclature and therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionPractice Guidelines as TopicAntihypertensive AgentsHumansEuropeUnited StatesBlood PressureSocieties, MedicalAmerican Heart AssociationAdultCardiovascular Diseases

Stichwörter der Autor:innen

cardiovascular eventschronic kidney diseasehypertensionmortality

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, Koc University School of Medicine, Istanbul, Turkey.
  • Department of Internal Medicine, Koc University School of Medicine, Istanbul, Turkey.
  • First Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Department of Renal Medicine, University Hospitals Birmingham, Birmingham, UK.
  • Department of Cardiovascular Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK.
  • Department of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.

ORCID-Profile: Mehmet Kanbay, Charles J Ferro, Alberto Ortiz

Förderung

  • Comunidad de Madrid en Biomedicina
  • Instituto de Salud Carlos III
  • European Union
  • FEDER
  • COST

Zitieren

APA

Kanbay, M., Copur, S., Sarafidis, P., Ferro, C. J., & Ortiz, A. (2026). 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfag055

Vancouver

Kanbay M, Copur S, Sarafidis P, Ferro CJ, Ortiz A. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation. 2026. doi:10.1093/ndt/gfag055

BibTeX
@article{Kanbay2026,
  author = {Kanbay, Mehmet and Copur, Sidar and Sarafidis, Pantelis and Ferro, Charles J and Ortiz, Alberto},
  title = {2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation and management of high blood pressure in adults: a commentary from the European Renal Best Practice (ERBP)},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  doi = {10.1093/ndt/gfag055}
}
Kostenlos starten →